• 1
    Cohn JN, Ferrari R & Sharpe N (2000) Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35, 569582.
  • 2
    Bui AL, Horwich TB & Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8, 3041.
  • 3
    McMurray JJ, Petrie MC, Murdoch DR & Davie AP (1998) Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 19(Suppl P), P9P16.
  • 4
    Finsen AV, Woldbaek PR, Li J, Wu J, Lyberg T, Tonnessen T & Christensen G (2004) Increased syndecan expression following myocardial infarction indicates a role in cardiac remodeling. Physiol Genom 16, 301308.
  • 5
    Alexopoulou AN, Multhaupt HAB & Couchman JR (2007) Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 39, 505528.
  • 6
    VanWinkle WB, Snuggs MB, De Hostos EL, Buja LM, Woods A & Couchman JR (2002) Localization of the transmembrane proteoglycan syndecan-4 and its regulatory kinases in costameres of rat cardiomyocytes: a deconvolution microscopic study. Anat Rec 268, 3846.
  • 7
    Finsen AV, Lunde IG, Sjaastad I, Østli EK, Lyngra M, Jarstadmarken HO, Hasic A, Nygård S, Wilcox-Adelman SA, Goetinck PF et al. (2011) Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin–NFAT pathway. PLoS One 6, e28302.
  • 8
    Herum KM, Lunde IG, Skrbic B, Florholmen G, Behmen D, Sjaastad I, Carlson CR, Gomez MF & Christensen G (2013) Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress. J Mol Cell Cardiol 54, 7381.
  • 9
    Matsui Y, Ikesue M, Danzaki K, Morimoto J, Sato M, Tanaka S, Kojima T, Tsutsui H & Uede T (2011) Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res 108, 13281339.
  • 10
    Echtermeyer F, Harendza T, Hubrich S, Lorenz A, Herzog C, Mueller M, Schmitz M, Grund A, Larmann J, Stypmann J et al. (2011) Syndecan-4 signalling inhibits apoptosis and controls NFAT activity during myocardial damage and remodelling. Cardiovasc Res 92, 123131.
  • 11
    Götte M (2003) Syndecans in inflammation. FASEB J 17, 575591.
  • 12
    Parish CR (2006) The role of heparan sulphate in inflammation. Nat Rev Immunol 6, 633643.
  • 13
    Yu Q, Vazquez R, Zabadi S, Watson RR & Larson DF (2010) T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice. Matrix Biol 29, 511518.
  • 14
    Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T & Frantz S (2012) Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation 125, 16521663.
  • 15
    Yu Q, Horak K & Larson DF (2006) Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension 48, 98104.
  • 16
    Poltorak A, He X, Smirnova I, Liu M-Y, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in tlr4 gene. Science 282, 20852088.
  • 17
    Kawai T & Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11, 373384.
  • 18
    Louch WE, Sheehan KA & Wolska BM (2011) Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol 51, 288298.
  • 19
    Wilkins BJ & Molkentin JD (2004) Calcium–calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322, 11781191.
  • 20
    Molkentin JD, Lu J-R, Antos CL, Markham B, Richardson J, Robbins J, Grant SR & Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215228.
  • 21
    Wilkins BJ, Dai Y-S, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR & Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94, 110118.
  • 22
    Manon-Jensen T, Itoh Y & Couchman JR (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 38763889.
  • 23
    Ramani VC, Pruett PS, Thompson CA, DeLucas LD & Sanderson RD (2012) Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 287, 99529961.
  • 24
    Woods A & Couchman JR (1994) Syndecan-4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell 5, 183192.
  • 25
    Saoncella S, Echtermeyer F, Denhez F, Nowlen JK, Mosher DF, Robinson SD, Hynes RO & Goetinck PF (1999) Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc Natl Acad Sci 96, 28052810.
  • 26
    Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Tsuzuki S, Nakamura E, Kusugami K, Saito H & Muramatsu T (2000) Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions. J Biol Chem 275, 52495252.
  • 27
    Couchman JR (2010) Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 26, 89114. doi:10.1146/annurev-cellbio-100109-104126.
  • 28
    Yndestad A, Damås J, Øie E, Ueland T, Gullestad L & Aukrust P (2007) Role of inflammation in the progression of heart failure. Curr Cardiol Rep 9, 236241.
  • 29
    Mann DL (2003) Stress-activated cytokines and the heart: from adaptation to maladaptation. Ann Rev Physiol 65, 81101.
  • 30
    Frantz S, Ertl G & Bauersachs J (2007) Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4, 444454.
  • 31
    Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad G, Williams D, Browder I et al. (2005) Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68, 224234.
  • 32
    Frantz S, Kobzik L, Kim Y-D, Fukazawa R, Medzhitov R, Lee RT & Kelly RA (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104, 271280.
  • 33
    Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J & Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729777.
  • 34
    Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M & Goetinck PF (2001) Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 107, R9R14.
  • 35
    Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Iwase M, Yoshikai Y, Yanada M, Yamamoto K, Matsushita T, Nishimura M et al. (2001) Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem 276, 4748347488.
  • 36
    Ishiguro K, Kojima T & Muramatsu T (2002) Syndecan-4 as a molecule involved in defense mechanisms: special issue on proteoglycans: genetic manipulation in intact organisms – on the road to function. Glycoconjugate J 19, 315318.
  • 37
    Xie J, Wang J, Li R, Dai Q, Yong Y, Zong B, Xu Y, Li E, Ferro A & Xu B (2012) Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction. J Mol Cell Cardiol 53, 250258.
  • 38
    Rodríguez-Manzaneque JC, Carpizo D, Plaza-Calonge MdC, Torres-Collado AX, Thai SNM, Simons M, Horowitz A & Iruela-Arispe ML (2009) Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol 41, 800810.
  • 39
    Choi S, Lee H, Choi JR & Oh ES (2010) Shedding; towards a new paradigm of syndecan function in cancer. BMB Rep 43, 305310.
  • 40
    Theocharis AD, Skandalis SS, Tzanakakis GN & Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 39043923.
  • 41
    Kojima T, Takagi A, Maeda M, Segawa T, Shimizu A, Yamamoto K, Matsushita T & Saito H (2001) Plasma levels of syndecan-4 (ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost 85, 793799.
  • 42
    Takahashi R, Negishi K, Watanabe A, Arai M, Naganuma F, Ohyama Y & Kurabayashi M (2011) Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J Cardiol 57, 325332.
  • 43
    Wang J, Markova D, Anderson DG, Zheng Z, Shapiro IM & Risbud MV (2011) TNF-α and IL-1β promote a disintegrin-like and metalloprotease with thrombospondin type I motifs(ADAMTS) -5 mediated aggrecan degradation through syndecan-4 in intervertebral disc. J Biol Chem 286, 3973839749.
  • 44
    Smith MF, Novotny J, Carl VS & Comeau LD (2006) Helicobacter pylori and toll-like receptor agonists induce syndecan-4 expression in an NF-κB-dependent manner. Glycobiology 16, 221229.
  • 45
    Tan X, Khalil N, Tesarik C, Vanapalli K, Yaputra V, Alkhouri H, Oliver BGG, Armour CL & Hughes JM (2012) Th1 cytokine-induced syndecan-4 shedding by airway smooth muscle cells is dependent on mitogen-activated protein kinases. Am J Physiol - Lung C 302, L700L710.
  • 46
    Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW, Kao RL & Li C (2004) NF-κB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol - Heart C 287, H1712H1720.
  • 47
    Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L et al. (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Failure 11, 119129.
  • 48
    Lunde IG, Kvaløy H, Austbo B, Christensen G & Carlson CR (2011) Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes. J Appl Physiol 111, 12781289.
  • 49
    Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P & Gardner MB (1974) Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33, 10271033.
  • 50
    Claycomb WC, Lanson NA, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A & Izzo NJ (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95, 29792984.
  • 51
    Brattelid T, Winer LH, Levy FO, Liestør K, Sejersted OM & Andersson KB (2010) Reference gene alternatives to Gapdh in rodent and human heart failure gene expression studies. BMC Mol Biol 11, 22.
  • 52
    Burbach BJ, Friedl A, Mundhenke C & Rapraeger AC (2003) Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol 22, 163177.
  • 53
    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18, 14401463.